| Date | Title | Description | |
|---|---|---|---|
| 16 Feb 2023 | On business and financial situation | The Company informs on the evaluation process to obtain marketing authorisation for Risvan® (Risperidone ISM®) in the United States. | Download |
| 09 Jan 2023 | Liquidity and counterparty agreements | Liquidity contract: transactions conducted in the fourth quarter of 2022 | Download |
| 15 Dec 2022 | On Corporate Governance | The Company informs about changes in the Board of Directors and the creation of an Advisory Committee. | Download |
| 04 Oct 2022 | On business and financial situation | The Company informs that it has signed a joint venture agreement with Càrniques Ceirà and Grupo Costa to construct a plant for the production of compounds of high technological value. | Download |
| 03 Oct 2022 | Liquidity and counterparty agreements | Liquidity contract: transactions conducted in the third quarter of 2022 | Download |
Pages
| Date | Title | Description | |
|---|---|---|---|
| 16 Feb 2017 | Información sobre resultados (2) | ROVI releases the press release related to the full year 2016 results | Download |
| 16 Feb 2017 | Información sobre resultados | ROVI releases the presentation related to the full year 2016 results | Download |
| 16 Feb 2017 | Informe Anual de Gobierno Corporativo | ROVI releases the 2016 Annual Corporate Governance Report | Download |
| 10 Jan 2017 | Contratos de liquidez y contrapartida | Liquidity contract: transactions conducted in the fourth quarter of 2016 | Download |
| 22 Nov 2016 | Acuerdos estratégicos con terceros | ROVI announces the marketing agreement of Neparvis in Spain | Download |